Sulfate of pleuromutilin compound and preparation method and application thereof
By reacting PMT with sulfuric acid in an organic solvent to form its sulfate form, the problem of low oral bioavailability caused by PMT being insoluble in water is solved, and its efficient application in the treatment of bacterial or mycoplasma infection is achieved.
Patent Information
- Application Number
- CN202411013661.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-26
AI Technical Summary
Truncated pleurin compounds 14-O-[(4-(pyrrolidinyl-1-yl)-6-methylpyridin-2-yl)thioacetyl]merlin (PMT) are difficult to dissolve in water, resulting in Its oral bioavailability is low.
The PMT is reacted with sulfuric acid in an organic solvent to form its sulfate form, and then cooled by heating and stirring to obtain a PMT sulfate with good stability and water soluble. The process includes stirring at 50-70°C for 0.5-3 hours, then cooling to room temperature and leaving for 1-3 days, resulting in a solid PMT sulfate.
The oral bioavailability of PMT has been significantly improved, making it an effective oral drug for the treatment of human or animal infection caused by bacteria or mycoplasma, with high water solubility and stability.
Smart Images

Figure CN118955406A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug salts, and in particular relates to a sulfate of a pleuromutilin compound and a preparation method and application thereof. Background Art
[0002] In the process of chemical drug development, the physicochemical properties of drugs are of great significance to the absorption, distribution, metabolism and excretion (ADME) of drugs in the body, dosage form development or production, etc. Most chemical raw materials (APIs) belong to Class II compounds in the BCS classification, which are water-insoluble compounds, resulting in low oral bioavailability, which is not conducive to the clinical use of drugs. In order to improve water solubility, chemical drugs are generally prepared into salt forms or co-crystals to change their physicochemical properties, improve water solubility, and increase their oral bioavailability.
[0003] Pleurotus multilus (Fr.) Sacc. and Pleurotus Passecke-rianus Pilat are diterpenoid compounds with antibacterial activity that were first isolated in the 1950s from the higher fungi Pleurotus multilus (Fr.) Sacc. and Pleurotus Passecke-rianus Pilat. The antibacterial activity of this class of compounds can be significantly improved by structural modification of its C-4 side chain. Four drugs, namely, tylosin, valnemulin, retamulin and lefamulin, have been developed through structural modification of pleurotus multilus. Among them, the first two are used as veterinary drugs to treat or prevent diseases caused by Brachyspirahyodysenteriae and Mycoplasma spp. The latter two are used as human drugs to treat wound infections, skin infections and community-acquired bacterial pneumonia caused by Staphylococcus and Streptococcus, respectively.
[0004] 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] pleuromutilin (PMT) is a truncated pleuromutilin compound containing a pyrimidine ring side chain. Studies have shown that the compound has good activity against Gram-positive bacteria and mycoplasma. In addition, the compound has the advantages of low toxicity and low production cost. However, since PMT is poorly soluble in water, the oral bioavailability of the compound is low. Summary of the invention
[0005] The first purpose of the present invention is to solve the problem that PMT is poorly soluble in water and has low oral bioavailability, and to provide a sulfate of pleuromutilin compounds with high oral bioavailability.
[0006] The second object of the present invention is to provide a method for preparing the sulfate of the above-mentioned pleuromutilin compounds.
[0007] The third object of the present invention is to provide the use of the sulfate of the above-mentioned pleuromutilin compounds.
[0008] The purpose of the present invention is specifically achieved through the following technical solutions:
[0009] A sulfate of a pleuromutilin compound, wherein the sulfate of the pleuromutilin compound is a sulfate of 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] merthrin having the following structure:
[0010]
[0011] The method for preparing the sulfate of the pleuromutilin compound is as follows: the 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] ethrin and sulfuric acid are dissolved in an organic solvent, heated and stirred for reaction, cooled to room temperature, and allowed to stand to obtain a solid, which is the sulfate of 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] ethrin.
[0012] Preferably, the usage ratio of the 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] ethoxylated is as follows: for every 5.6 g of 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] ethoxylated, 40-50 mL of a 29.4 mg / mL aqueous sulfuric acid solution and 80-150 mL of an organic solvent are added.
[0013] Preferably, the organic solvent includes one or a mixed solvent of alcohols, esters, ketones and acetonitrile solvents.
[0014] Preferably, the heating temperature is 50-70° C.; the reaction time is 0.5-3 h; and the standing time is 1-3 days.
[0015] Application of the sulfate of the pleuromutilin compound in the preparation of oral medicines for treating human or animal infections caused by bacteria or mycoplasma.
[0016] Preferably, the bacteria include Staphylococcus aureus, methicillin-resistant Epidermidis, methicillin-resistant Staphylococcus aureus, and Streptococcus agalactiae; the mycoplasma include Mycoplasma gallisepticum, Mycoplasma synoviae, Mycoplasma hyorhinis, Mycoplasma hyopneumoniae, and Mycoplasma bovis.
[0017] Compared with the prior art, the present invention has the following advantages:
[0018] The sulfate of the compound 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] merazole provided by the present invention has good stability and water solubility, and significantly improves the oral bioavailability of the compound PMT, and has the potential to be developed into an oral drug for treating human or animal infections caused by bacteria or mycoplasma. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 is the PXRD pattern of the pleuromutilin compound PMT sulfate prepared in Example 1;
[0020] Figure 2 is the FT-IR image of the pleuromutilin compound PMT sulfate prepared in Example 1;
[0021] Figure 3 1 is the DSC and TG graph of the pleuromutilin compound PMT sulfate prepared in Example 1;
[0022] Figure 4 The dissolution curves of PMT and its sulfate in different pH buffers: (A) is the dissolution curve of PMT and its sulfate in pH 1.2 buffer; (B) is the dissolution curve of PMT sulfate in pH 4.5 and 6.8 buffers;
[0023] Figure 5 is the positive ion spectrum of PMT;
[0024] Figure 6 It is the positive ion spectrum of IS (Tiamulin);
[0025] Figure 7 This is the average blood concentration-time curve of PMT in rats: (A) is intravenous injection of PMT original drug; (B) is oral administration of PMT original drug; (C) is oral administration of PMT sulfate. DETAILED DESCRIPTION
[0026] The preferred embodiments of the present invention are described below. It should be understood that the preferred embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0027] Unless otherwise specified, the raw materials used in the examples are all commercially available products. Among them, PMT was prepared in this laboratory. The preparation method can be found in reference (Eur. J. Med. Chem. 2020, 207, 12735.).
[0028] The product characterization method obtained in the following examples is as follows:
[0029] Powder X-ray diffraction (PXRD) detection method:
[0030] Before use, the instrument is calibrated with the standard sample that comes with it. The test sample is placed on a plexiglass slide and tested at room temperature. CuKa radiation is used Voltage 40 kV, current 40 mA. Detection conditions: 2θ angle 5-40°, step length 0.02°, speed 5 s / step.
[0031] Fourier transform infrared spectroscopy (FT-IR) detection method:
[0032] Nicolet FT-IRMagna 550 instrument was used for detection. About 5 mg of sample was pressed into a transparent film by KBr and placed on the sample stage for detection. The resolution was 4 cm -1 , the spectral range is 4000-400cm -1 .
[0033] Differential Scanning Calorimetry (DSC) Method:
[0034] Differential scanning calorimeter (TAQ2000) was used for analysis, and metal indium was used for calibration before analysis. 3-5 mg of sample was sealed in an aluminum crucible with high-purity nitrogen protection (nitrogen flow rate 50 mL / min), and the temperature was raised to 600°C at a rate of 10°C / min.
[0035] Thermogravimetric (TG) analysis method:
[0036] Thermogravimeter (TA Q500) was used for analysis. 5-10 mg of sample was placed in a platinum pan, protected by high-purity nitrogen (nitrogen flow rate 40 mL / min), and the temperature was raised to 600°C at a rate of 20°C / min.
[0037] Example 1
[0038] According to the molar ratio of PMT and sulfuric acid of 1:1.5, 0.56g (1mmol) of PMT was dispersed in 10mL of acetone, and stirred at 50±1°C until completely dissolved. Then, 5mL of an aqueous solution containing 1.5mmol of sulfuric acid (total 29.4mg / mL) was added, and stirred at this temperature for 1h. Then, 5mL of distilled water was added again (distilled water may not be added), and stirred for 1h. Then, the mixture was cooled to room temperature and placed for 2d. The obtained solid was filtered and rinsed twice with 10mL of distilled water. The filter cake was dried at 50°C for 5h to obtain 0.59g of a light yellow solid, which is PMT sulfate.
[0039] Example 2
[0040] According to the molar ratio of PMT and sulfuric acid of 1:1.5, 0.56g (1mmol) of PMT was dispersed in 15mL of ethanol, stirred at 55±1°C until completely dissolved, then 5mL of an aqueous solution containing 1.5mmol of sulfuric acid (total 29.4mg / mL) was added, stirred at this temperature for 1h, and then 5mL of distilled water was added again (distilled water may not be added), stirred for 1h, cooled to room temperature and left for 3d, the obtained solid was filtered, and rinsed twice with 10mL of distilled water, and the filter cake was dried at 50°C for 7h to obtain 0.57g of a light yellow solid, which is PMT sulfate.
[0041] Example 3
[0042] According to the molar ratio of PMT and sulfuric acid of 1:1.5, 0.56g (1mmol) of PMT was dispersed in 15mL of acetonitrile, and stirred at 60±1°C until completely dissolved. Then, 5mL of an aqueous solution containing 1.5mmol of sulfuric acid (total 29.4mg / mL) was added, and stirred at this temperature for 1h. Then, 5mL of distilled water was added again (distilled water may not be added), and after stirring for 1h, it was cooled to room temperature and placed for 3d. The obtained solid was filtered and rinsed twice with 10mL of distilled water. The filter cake was dried at 50°C for 7h to obtain 0.60g of a light yellow solid, which is PMT sulfate.
[0043] The PMT sulfate prepared in the examples was characterized by solid-state chemical methods such as PXRD, FT-IR, DSC, TG, etc., and the results were basically the same. Figure 1-3 .
[0044] Example 4
[0045] Dissolution kinetics studies
[0046] The solubility of PMT and PMT sulfate obtained in Example 1 was measured in ammonium acetate buffer at three conditions: pH 1.2, 4.5 and 6.8.
[0047] Determination method: The test sample was ground and sieved (100 mesh) to eliminate the difference caused by different particle sizes. 20 mg of the sieved sample was weighed and added to 10 mL of ammonium acetate buffer of different pH values, and vortexed at 300 rpm at 37 °C to dissolve, then 1 mL of the solution was taken at 2.5, 5, 10, 20, 40, 60, 120 and 240 min, filtered through a 0.45 μm filter membrane, and the content of PMT and its sulfate was determined by HPLC.
[0048] Ultra-high performance liquid chromatograph: Agilent Infinity 1290, equipped with binary pump and diode array detector (DAD); Agilent, USA.
[0049] Chromatographic conditions: the chromatographic column was ZORBAX Eclipse Plus C18, (4.6 μm×250 mm); the flow rate was 1 mL / min; the detection wavelength was set at 265 nm; the column temperature was 22°C; the mobile phase was water and acetonitrile (80:20).
[0050] Experimental results: The dissolution curves of PMT and its sulfate at different sampling times in different pH buffers are shown in the appendix of the manual. Figure 4 At pH 1.2 ( Figure 4 A), PMT sulfate showed much faster solubility than PMT, with the maximum solubility concentration (C max ), 1972±74μg / mL, and then the solubility gradually decreased, and was lower than the PMT of the original drug at about 57min, but the area under the curve (AUC) of PMT sulfate was 1.12 times higher than that of PMT. Figure 4 B), the original drug PMT was not detected in the buffer. PMT sulfate showed a similar dissolution curve, with the maximum dissolution concentration at 2.5 min, which were 87.66±18.48 and 0.55±0.14 μg / mL, respectively, indicating that the PMT sulfate provided by the present invention has high water solubility.
[0051] Example 5
[0052] Preclinical pharmacokinetic studies
[0053] The pharmacokinetic study was conducted by intravenous injection of PMT original drug, oral administration of PMT original drug and its sulfate to SD rats, and the content of PMT original drug in rat plasma at different times was determined.
[0054] Detection method: LC-MS / MS analysis was performed using AB SCIEX QTRAP 5500 ultra high performance liquid chromatography-mass spectrometry.
[0055] Liquid phase conditions: The chromatographic column was a Zorbax Eclipse Plus C18 column (50 mm × 2.1 mm ID, 1.8 μm), and gradient elution was performed according to the mobile phase ratio in Table 1. The flow rate was 0.2 mL / min, the column temperature was 40 °C, the running time was 7 min, and the injection volume was 2.5 μL.
[0056] Table 1 Gradient elution time and mobile phase ratio
[0057] Time (min) Flow rate (mL / min) A (0.1% formic acid water) B(Acetonitrile) 0 0.2 90 10 1 0.2 90 10 1.5 0.2 20 80 3.8 0.2 20 80 4.8 0.2 90 10 7 0.2 90 10
[0058] Mass spectrometry conditions: positive ion mode, ion source is electrospray ion source (ESI), and multiple reaction monitoring (MRM) mode is used for scanning. The parameters are set as follows: electrospray voltage is +5500V, ion source temperature is 550℃, entrance potential (EP) is 10V, collision cell exit potential (CXP) is 13V, nebulizer and auxiliary pressure are 55psi, air curtain pressure is 20psi, and collision gas pressure is set to medium.
[0059] All data were obtained by integrating the German Bruker 3.4MS Workstation V8.2 software. The specific PMT and internal standard IS (tiamulin) quantitative and qualitative ion pair parameters are shown in Table 2.
[0060] Table 2 Quantitative and qualitative ion pair parameters of PMT and internal standard (Tiamulin)
[0061]
[0062] Preparation of sample solution: PMT stock solution and working solution were prepared using chromatographically pure acetonitrile, and the working solution concentrations were 1, 5, 10, 50, 100, 500, 1000, 1500, and 3000 ng / mL. Internal standard stock solution and working solution (100 ng / mL) were also prepared using chromatographically pure acetonitrile.
[0063] Plasma sample processing method: 100 μL and 10 μL internal standard (internal standard concentration is 100 ng / mL) are added to a 4 mL centrifuge tube, vortexed for 30 seconds, then 2 mL of acetonitrile is added, vortexed for 5 minutes, centrifuged at 12000 rpm for 10 minutes at 4°C, the supernatant is taken to a 4 mL centrifuge tube, the solvent is evaporated at 40°C, re-dissolved with 100 μL of mobile phase, vortexed for 10 minutes, centrifuged again at 12000 rpm for 10 minutes at 4°C, transferred to an injection vial, and 2.5 μL is injected. The PMT ion spectrum obtained is as follows Figure 5 As shown in Figure 2, the ion spectrum of the internal standard tylosin is as follows: Figure 6 shown.
[0064] The above extraction and detection methods of PMT in plasma were validated for specificity, precision and accuracy, extraction recovery, matrix effect and stability, indicating that the established method was stable and reliable and could be applied to subsequent pharmacokinetic studies of PMT and its salt forms.
[0065] Drug metabolism and kinetics study: 18 Sprague-Dawley rats (half male and half female, weighing 180-200g) were used for drug metabolism and kinetics study. The 18 rats were randomly divided into 3 groups, namely, PMT original drug intravenous injection group, PMT original drug oral administration group and PMT sulfate oral administration group, 6 rats in each group, fasted for 12h before the experiment. Rats in the intravenous injection group were intravenously injected with a dose of 5mg / kg. Before administration, the PMT original drug was dissolved in DMSO, Tween-80 and saline in a ratio of 0.5:0.5:9. The original drug oral group and sulfate oral group were orally administered at a dose of 60mg / kg, respectively. Before administration, the PMT original drug or its sulfate was dissolved in DMSO, Tween-80 and saline in a ratio of 0.5:1:8.5.
[0066] Before administration and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours after administration, 0.5 mL of blood was collected from the eye sockets of the rats in the intravenous injection group, and the blood was centrifuged at 5000 rpm for 10 minutes to obtain plasma samples, which were stored at -20°C for later use. Before administration and at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours after administration, 0.5 mL of blood was collected from the eye sockets of the rats in the original drug oral group and the sulfate oral group, and the blood was centrifuged at 5000 rpm for 10 minutes to obtain plasma samples, which were stored at -20°C for later use.
[0067] The above plasma samples were all tested for blood drug concentration using the established LC-MS / MS method, and the measured blood drug concentration-time curve was fitted using PK Solver software. The non-compartmental model was used to analyze the pharmacokinetic parameters of each animal, and the oral absolute and relative bioavailability of PMT was calculated according to the following formula.
[0068] F abs. =(AUC extravascular / (AUC i.v )×(dose i.v. / dose extravascular )×100%;
[0069] F rel =(AUC salt / (AUC extravascular )×(dose extravascular. / dose salt )×100%.
[0070] According to the established LC-MS / MS method, the data of plasma samples at different time points after administration to rats were collected, and the blood drug concentrations of different administration routes were calculated. The average blood drug concentration-time curve is shown in the attached Figure 7 .
[0071] The blood drug concentration time data was analyzed by non-compartmental model using PK Solver software to calculate the main pharmacokinetic parameters of PMT and its sulfate, and the results are shown in Table 3. According to the formula Fabs = (AUCT·Div) / (AUCiv·DT)×100%, the absolute bioavailability of PMT original drug and its sulfate was calculated to be 0.57% and 5.92%, respectively. The above studies show that the PMT sulfate provided by the present invention is superior to its original drug PMT in terms of drug metabolism parameters and oral bioavailability, especially its bioavailability is increased by 10.39 times.
[0072] Table 3 Average drug metabolism parameters of PMT in rat plasma (n=6, mean±SD).
[0073]
[0074] F=(AUCT·Div) / (AUCiv·DT)×100%
[0075] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention is described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A sulfate of a pleuromutilin compound, characterized in that: The sulfate of the pleuromutilin compound is a sulfate of 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] thiourea having the following structure:
2. The method for preparing the sulfate of pleuromutilin compounds according to claim 1, characterized in that: The 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] ethoxylate and sulfuric acid are dissolved in an organic solvent, heated and stirred for reaction, cooled to room temperature, and allowed to stand to obtain a solid, which is the sulfate of 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] ethoxylate.
3. The method for preparing the sulfate of pleuromutilin compounds according to claim 2, characterized in that: The usage ratio of the 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] ethoxylated is as follows: for every 5.6 g of 14-O-[(4-(pyrrolidin-1-yl)-6-methylpyridin-2-yl)thioacetyl] ethoxylated, 40-50 mL of a 29.4 mg / mL aqueous sulfuric acid solution and 80-150 mL of an organic solvent are added.
4. The method for preparing the sulfate of pleuromutilin compounds according to claim 2, characterized in that: The organic solvent includes one or a mixed solvent of alcohols, esters, ketones and acetonitrile solvents.
5. The method for preparing the sulfate of pleuromutilin compounds according to claim 2, characterized in that: The heating temperature is 50-70° C.; the reaction time is 0.5-3 h; and the placement time is 1-3 days.
6. Use of the sulfate of the pleuromutilin compound according to claim 1 in the preparation of an oral medicament for treating human or animal infections caused by bacteria or mycoplasma.
7. The use according to claim 6, characterized in that: The bacteria include Staphylococcus aureus, methicillin-resistant Epidermidis, methicillin-resistant Staphylococcus aureus, and Streptococcus agalactiae; the mycoplasma include Mycoplasma gallisepticum, Mycoplasma synoviae, Mycoplasma hyorhinis, Mycoplasma hyopneumoniae, and Mycoplasma bovis pneumoniae.
Citation Information
Patent Citations
Pleuromutilin compound, preparation method of pleuromutilin compound, polymorphism and preparation method of polymorphism
CN105399684A
Pleuromutilin derivative containing N-alkylated pyrimidine side chain and application of pleuromutilin derivative
CN111253322A
Pleuromutilin derivative with pyrimidine side chain as well as preparation method and application of pleuromutilin derivative
CN114853782A
Pleuromutilin derivative as well as preparation method and application thereof
CN116924984A
Pleuromutilin compound with triazine side chain as well as preparation method and application of pleuromutilin compound
CN117069668A
